We are acutely aware of the ongoing changes in sexual behavioral among today’s younger generations across the globe. In response, we are developing a product to meet the evolving needs of this future generation—and those to come.

As we progress towards first-in human trials, we are also advancing two additional pipeline products: one is a pro-conception gel designed to stimulate low-motility sperm, while the other is a targeted formulation specifically aimed at HIV. Currently, we have achieved excellent laboratory results against both oral and genital herpes viruses, Neisseria gonorrhoeae (gonorrhea), bacterial vaginosis (BV), and vaginal thrush (a yeast infection). These findings cover a broad spectrum—viruses, bacteria, and yeast infections—highlighting the potential impact of our innovation.

We invite you to invest in the next generation of scientific advancements that will empower women. Our Femgela lubricant gel is designed to significantly reduce harmful viruses, bacteria, and yeasts without disrupting the natural, beneficial vaginal microflora. It is also safe for oral sex—without introducing harmful chemicals unsafe for ingestion.

Invest in women’s sexual health and empowerment.